Related Experiment Video
Updated: Jul 13, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Pyrimidine benzamide-based thrombopoietin receptor agonists
Lawrence A Reiter1, Chakrapani Subramanyam, Emilio J Mangual
1Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA.
Bioorganic & Medicinal Chemistry Letters
|August 21, 2007
Summary
Researchers developed novel pyrimidine benzamide thrombopoietin receptor agonists. Modifications addressed potential thiazole toxicity and improved potency, but bioavailability remains limited by poor solubility and permeability.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Thrombopoietin receptor agonists are crucial for treating thrombocytopenia.
- Pyrimidine benzamide scaffolds offer a promising structural basis for developing novel agonists.
- Idiosyncratic toxicity associated with certain chemical moieties necessitates careful molecular design.
Purpose of the Study:
- To design and synthesize novel pyrimidine benzamide-based thrombopoietin receptor agonists.
- To mitigate potential toxicity linked to the 2-amino-5-unsubstituted thiazole moiety.
- To optimize compound potency and evaluate in vivo pharmacokinetic properties.
Main Methods:
- Synthesis of a series of pyrimidine benzamide derivatives.
- Chemical modification of the thiazole ring (C-5 substitution or replacement with thiadiazole).
- Structure-activity relationship studies to enhance potency.
- In vivo pharmacokinetic assessment of lead compounds.
Main Results:
- Successfully synthesized pyrimidine benzamide analogs with improved potency.
- Eliminated potential metabolic oxidation at the thiazole C-5 position through chemical modification.
- Identified lead compounds with enhanced potency compared to earlier analogs.
- Observed limited in vivo bioavailability due to poor aqueous solubility and cell membrane permeability.
Conclusions:
- Pyrimidine benzamide derivatives represent a viable class of thrombopoietin receptor agonists.
- Strategies for mitigating thiazole-related toxicity were successfully implemented.
- Further optimization is required to overcome solubility and permeability challenges for improved in vivo efficacy.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...